IDH1 mt-specific super-enhancer targets marked by 5hmC in our cohort and previously implicated in GBM pathogenesis included PDGFC, PRRX1, LIF, AXL, and CD44 [14, 18, 31, 50, 55, 63, 71]. The gene discussed is PRRX1; the disease is glioblastoma.